Nattokinase for Blood Pressure Regulation

Research suggests that nattokinase may have potential relevance to blood pressure regulation, with laboratory evidence indicating that peptides released during its digestion can inhibit angiotensin-converting enzyme (ACE), a biological target involved in blood pressure elevation. The available evidence consists of a single in vitro and computational study, which identified two specific peptides derived from nattokinase digestion that interacted with ACE through distinct inhibitory mechanisms, with network pharmacology analysis further suggesting involvement in broader cardiovascular pathways. It is important to note that this research is entirely preclinical in nature, relying on simulated digestion, molecular modeling, and computational tools rather than animal models or human clinical trials, which means the findings cannot yet be used to draw conclusions about effects in living systems. The overall body of evidence on this specific mechanism is extremely limited, and considerably more research — including human studies — would be needed before any meaningful conclusions about nattokinase and blood pressure in people could be established.